Ali Ala, Al-Taee Huda, Kadhim Thaer J
Nephrology and Renal Transplantation Centre, The Medical City, Baghdad, Iraq.
Department of Pathology, Al-Yarmouk Teaching Hospital, Iraq.
Case Rep Transplant. 2022 May 2;2022:6754520. doi: 10.1155/2022/6754520. eCollection 2022.
Allograft membranous glomerulopathy can be a recurrent or de novo disease. Both instead have different underlying immune pathophysiology and disease pattern. While the introduction of ANTI-PLAR2 and THS7A brought new insights into the management of Immune/primary MN, the treatment of de novo MN is not clear. Relapsing de novo MN in a kidney transplant was rarely reported. Here, we present a case of relapsing de novo MN without evidence of rejection and a gratifying response to rituximab.
同种异体移植膜性肾小球病可以是复发性疾病或新发疾病。两者相反,具有不同的潜在免疫病理生理学和疾病模式。虽然抗PLAR2和THS7A的引入为免疫性/原发性膜性肾病的管理带来了新的见解,但新发膜性肾病的治疗尚不清楚。肾移植中复发性新发膜性肾病鲜有报道。在此,我们报告一例无排斥反应证据的复发性新发膜性肾病病例,以及对利妥昔单抗的良好反应。